MSK-IMPACT 341 (IMPACT341)

Overview

Targeted (341 cancer genes) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers — canonical cBioPortal gene panel IMPACT341. The earliest of the MSK-IMPACT panel versions used in the corpus.

Used by

  • PMID:37078708 — used (alongside IMPACT410 / IMPACT468 depending on era) to profile 132 adults with nodal peripheral T-cell lymphoma at MSK 2015–2020; TP53 mutations and TP53/17p deletions were the only somatic aberrancies correlating with inferior PFS on CHOP-based induction PMID:37078708.
  • PMID:37591896 — one of the MSK-IMPACT panel versions used to profile 233 resected NSCLC brain metastases plus matched primary and extracranial samples PMID:37591896.
  • PMID:39214094 — IMPACT341 was one of the MSK-IMPACT panel generations (n=17 patients) used in the 397-patient sequenced subset of 1,360 resected PDAC cases at MSK; used alongside IMPACT410 and IMPACT468 for allele-specific KRAS profiling showing KRASG12R enrichment in stage I disease PMID:39214094.
  • PMID:39753968 — IMPACT341 was one of four panel generations (n=17 patients) used in the 2,336-patient MSK PDAC cohort; KRAS mutant-allele dosage gains inferred with FACETS across all panel generations PMID:39753968.
  • Profiled 117 advanced thyroid tumors (84 PDTC, 33 ATC) at mean depth 584x tumor / 236x normal (739x for ATCs); detected TP53 73% vs 8%, BRAF 45% vs 33%, PIK3CA 18% vs 9% in ATC vs PDTC — 2-3x higher detection rates than WES due to deep sequencing depth. PMID:26878173
  • Used to profile 6 plasmacytoid-variant bladder tumors in a prospective MSKCC cohort; identified CDH1 truncating mutations in 6/6 plasmacytoid tumors and 0/56 urothelial carcinoma NOS tumors. PMID:26901067
  • Used MSK-IMPACT341 panel for targeted tumor sequencing in a large clinical cohort PMID:28336552
  • 341-gene panel used in 26% (2,809/10,945) of the MSK-IMPACT prospective cohort; superseded by the 410-gene version which covers 74% of cases PMID:28481359
  • 341-gene MSK-IMPACT panel version used alongside the 410-gene version to sequence NMIBC tumors from the blca_nmibc_2017 cohort at Memorial Sloan Kettering PMID:28583311
  • 341-gene version of MSK-IMPACT applied to a subset of 295 metastatic EGC patients in the MSKCC prospective sequencing cohort PMID:29122777
  • Used in 214 of 1,134 prospectively sequenced COADREAD cases at MSKCC (mean coverage 747×) as part of the MSK-IMPACT CRC landscape study PMID:29316426
  • Applied to 56 advanced NSCLC patients treated with anti-PD-(L)1 therapy (mean coverage 744×); TMB from this panel correlated with WES TMB at Spearman r=0.86 PMID:29337640
  • Used in 18 of 106 centrally sequenced SUMMIT basket-trial patients for ERBB2/ERBB3-mutant solid tumors (mean coverage 738×) PMID:29420467

Notes

  • Targeted panel rather than WES/WGS — non-panel drivers and full mutational signatures are not assessed PMID:37078708.

Sources

This page was processed by crosslinker on 2026-05-04. - PMID:26878173

This page was processed by entity-page-writer on 2026-05-15. - PMID:26901067

This page was processed by entity-page-writer on 2026-05-15. - PMID:28336552

This page was processed by wiki-cli on 2026-05-14. - PMID:28481359

This page was processed by entity-page-writer on 2026-05-15. - PMID:28583311

This page was processed by entity-page-writer on 2026-05-15. - PMID:29122777

This page was processed by entity-page-writer on 2026-05-15. - PMID:29316426

This page was processed by wiki-cli on 2026-05-15. - PMID:29337640

This page was processed by wiki-cli on 2026-05-15. - PMID:29420467

This page was processed by wiki-cli on 2026-05-15.